tbuckley/cabot-search huggingface dataset:
Comparison of LIC Obtained from Biopsy, BLS and R2-MRI in Iron Overloaded Patients with β-Thalassemia, Treated with Deferasirox (Exjade®, ICL670).
Authors: A. Piga, R. Fischer, P. Harmatz, T. G. St. Pierre, F. Longo, E. Fung, R. Engelhardt, S. Perrotta, R. Galanello, M. Capra, E. Vichinsky, G. Janka-Schaub, G. Masera, P. Cianciulli, T. Coates, G. Janssen, M. Jeng, M. E. Lai, G. Salles, P. Cole, D. Alberti, G. Rosenkranz, H. Opitz
Journal: Blood (2005)
Optical Mapping of the Myeloma Cancer Genome to Elucidate Mechanisms of Acquired Resistance to Proteasome Inhibitors.
Authors: Aditya Gupta, Jaehyup Kim, Chelsea Hope, Jeff Jensen, Natalie Callander, Peiman Hematti, Emery H Bresnick, David C Schwartz, Fotis Asimakopoulos
Journal: Blood (2012)
Use of oligonucleotide hybridization in the characterization of a beta zero-thalassemia gene (beta 37 TGG----TGA) in a Saudi Arabian family [published erratum appears in Blood 1986 Jul;68(1):323]
Authors: CD Boehm, CE Dowling, PG Waber, PJ Giardina, HH Jr Kazazian
Journal: Blood (1986)
Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Authors: Brian G. Till, Steven I. Park, Leslie L. Popplewell, Andre Goy, Elicia Penuel, Jeffrey M Venstrom, Bo Liu, Guenter Fingerle-Rowson, John Byon, Paul Woodard, M. Lia Palomba
Journal: Blood (2015)
Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone
Authors: Simone Boehrer, Odile Beyne-Rauzy, Thomas Prebet, Sophie Park, Agnès Guerci, Aspasia Stamatoulas, MP Chaury, Tony Jernival, Laurence Sanhes, Gerard Tertian, Stephane Cheze, Eng-Mong Lim, Bachra Choufi, Denis Caillot, E. Wattel, Jacques Delaunay, Laurence Legros, Fatiha Chermat, Françoise Isnard, N. Cambier, Borhane Slama, Lydia Roy, Gandhi Damaj, Emmanuel Raffoux, Francois Dreyfus, Christian Récher, Norbert Vey, Sylvie Chevret, Pierre Fenaux, Claude Gardin
Journal: Blood (2010)
Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis
Authors: Louisa Sukkar, Daqing Hong, Muh Geot Wong, Sunil V Badve, Kris Rogers, Vlado Perkovic, Michael Walsh, Xueqing Yu, Graham S Hillis, Martin Gallagher, Meg Jardine
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To summarise the benefits and harms of ischaemic conditioning on major clinical outcomes in various settings. <b>Design</b>&nbsp;Systematic review and meta-analysis. <b>Data sources</b>&nbsp;Medline, Embase, Cochrane databases, and International Clinical Trials Registry platform from inception through October 2015. <b>Study selection</b>&nbsp;All randomised controlled comparisons of the effect of ischaemic conditioning on clinical outcomes were included. <b>Data extraction</b>&nbsp;Two authors independently extracted data from individual reports. Reports of multiple intervention arms were treated as separate trials. Random effects models were used to calculate summary estimates for all cause mortality and other pre-specified clinical outcomes. All cause mortality and secondary outcomes with P&lt;0.1 were examined for study quality by using the GRADE assessment tool, the effect of pre-specified characteristics by using meta-regression and Cochran C test, and trial sequential analysis by using the Copenhagen Trial Unit method. <b>Results</b>&nbsp;85 reports of 89 randomised comparisons were identified, with a median 80 (interquartile range 60-149) participants and median 1 (range 1 day-72 months) month intended duration. Ischaemic conditioning had no effect on all cause mortality (68 comparisons; 424 events; 11 619 participants; risk ratio 0.96, 95% confidence interval 0.80 to 1.16; P=0.68; moderate quality evidence) regardless of the clinical setting in which it was used or the particular intervention related characteristics. Ischaemic conditioning may reduce the rates of some secondary outcomes including stroke (18 trials; 5995 participants; 149 events; risk ratio 0.72, 0.52 to 1.00; P=0.048; very low quality evidence) and acute kidney injury (36 trials; 8493 participants; 1443 events; risk ratio 0.83, 0.71 to 0.97; P=0.02; low quality evidence), although the benefits seem to be confined to non-surgical settings and to mild episodes of acute kidney injury only. <b>Conclusions</b>&nbsp;Ischaemic conditioning has no overall effect on the risk of death. Possible effects on stroke and acute kidney injury are uncertain given methodological concerns and low event rates. Adoption of ischaemic conditioning cannot be recommended for routine use unless further high quality and well powered evidence shows benefit.
Patients’ “gut feelings” about symptoms should be taken seriously, say researchers
Authors: Jacqui Wise
Journal: BMJ (2016)

Some patients report not being taken seriously by doctors and this can deter them from making a repeat consultation for persistent symptoms, a qualitative analysis published in the British Journal of General Practice has found.1

The researchers analysed free text comments at the end of a recent International Cancer Benchmarking Partnership survey carried out in Wales. Of the 905 patients with newly diagnosed breast, ovarian, colorectal, or lung cancer who returned the questionnaire, 530 included comments in the free text section.

The analysis showed a range of factors that patients …
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs)
Authors: Simona Bernardi, Andrea Di Palma, Mario Tiribelli, Erika Codarin, Giuseppina Ruggeri, Maria Teresa Bochicchio, Michele Malagola, Federica Cattina, Simone Perucca, Valeria Cancelli, Crisitina Skert, Gianantonio Rosti, Fausto Castagnetti, Luigi Caimi, Giuseppe Rossi, Giovanni Martinelli, Domenico Russo
Journal: Blood (2015)
Exploring the Potential Usefulness of 5-Aminolevulinic Acid for X-Linked Sideroblastic Anemia
Authors: Tohru Fujiwara, Ryoyu Niikuni, Koji Okamoto, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Yukio Nakamura, Tohru Tanaka, Hideo Harigae
Journal: Blood (2014)
Relationship between JAK2 V617F Mutation Status and Constitutive Mobilization of CD34-Positive Cells into Peripheral Blood in Patients with Chronic Myeloproliferative Disorder.
Authors: Francesco Passamonti, Elisa Rumi, Emanuela Boveri, Daniela Pietra, Laura Vanelli, Luca Arcaini, Matteo G. Della Porta, Cristiana Pascutto, Umberto Magrini, Mario Lazzarino, Mario Cazzola
Journal: Blood (2005)
Marrow Plasma Cell Immunohistochemical Expression Profiles of Cyclins (A, D1, D2, D3), Cyclin Dependent Kinase Inhibitors (p16, p21) and Ki67: Predictors of Survival in Patients with Multiple Myeloma.
Authors: Meral Beksac, Ender Soydan, Selami Kocak Toprak, Merih Kizil, Gulsah Kaygusuz, Isinsu Kuzu
Journal: Blood (2005)
Pharmacodynamic (PD) Biomarker Assay Validation for SB1518, a Novel Oral JAK2 Inhibitor in Phase 1 Clinical Trials for Advanced Leukemias, Myeloproliferative Diseases and Lymphoma.
Authors: Stefan Hart, Kee Chuan Goh, Yong Cheng Tan, Amalini Chithra, Jeanette Wood
Journal: Blood (2009)
SAT0467 Neuropathic Pain in Knee Osteoarthritis: Is Its Prevalence Related To A Greater Impact?
Authors: O. Akkar, L. Lehlou, L. Ichchou
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Knee osteoarthritis (OA) is a common and progressive joint disease with an estimated incidence rate of 240 per 100000 person-years. Pain from Knee OA is generally classified as nociceptive; however, a neuropathic component is possible. <h3>Objectives</h3> The objective of this study was to determine the prevalence of neuropathic pain (NP) in patients with painful knee OA using the DN4 questionnaire and to evaluate the relationship between NP, pain intensity, WOMAC function and stage of OA. <h3>Methods</h3> We included in this study patients with knee osteoarthritis according to ACR criteria. Pain score using Visual Analogue Scales (VAS), Western Ontario and McMaster Universities Osteo-arthritis Index (WOMAC), DN4 score, duration of symptoms, severity of OA using the Kellgren-Lawrence (KL) system, were evaluated using a Pearson9s correlation coefficient. p&lt;0.05 was considered statistically significant. <h3>Results</h3> One hundred patients (96 females, 4 males) with a mean±SD age of 59.4±10.4 years were included in the study. Mean±SD duration of symptoms was 72±54 months. The mean ± SD VAS was 5.2±2 and the total WOMAC 50±19. The prevalence of neuropathic pain was 26%. DN4 score was significantly correlated with the VAS (r=0.6, p=0.0001) and the WOMAC (r=0.53, p=0.0001). However, there was no significant correlation between DN4 score and KL grade. <h3>Conclusions</h3> DN4 score classified 26% of pain from knee OA as NP. Patients with severe pain and disability may have a NP component in their knee OA pain. It is important to be aware of considering the existence of NP in the treatment of knee OA pain. <h3>Disclosure of Interest</h3> None declared
An Intron Splicing Enhancer Element, UGCAUG, Is Evolutionarily Conserved near Erythroid Protein 4.1R Exon 16 and Other Tissue-Specific Alternative Exons.
Authors: Sherry L. Gee, Robert L. Lersch, Simon Minovitsky, Julie L. Ponthier, Annie J. Lo, Sarah Short, Joel A. Chasis, Inna Dubchak, John G. Conboy
Journal: Blood (2004)
THU0595 Impact of Physician-Patient Interactions on Disease Activity in Patients with Systemic Lupus Erythematosus:
Authors: C. Drenkard, G. Bao, H. Kan, B. Pobiner, P. Julie, W. Eastman, S.S. Lim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Physician-patient interactions can influence both quality of care and patient self-management decisions, which in turn can impact patients9 health outcomes. <h3>Objectives</h3> Examine the influence of physician-patient interactions on disease activity in a sample of SLE patients at high risk for poor outcomes. <h3>Methods</h3> The Georgians Organized Against Lupus (GOAL) is a predominantly African-American (AA) cohort largely drawn from a population-based registry of patients with SLE in Atlanta, GA, US. A subset of 125 GOAL participants from the most recent survey collection were provided two validated patient-reported multidimensional surveys to complete. The Interpersonal Processes of Care (IPC) was used to assess patient perceptions of their interactions with physicians within 3 domains: Communication, Shared Decision Making and Interpersonal Style. The Systemic Lupus Activity Questionnaire (SLAQ) was used to measure disease activity and SLAQ scores were adjusted for age, disease duration, sex, race, education, and insurance. <h3>Results</h3> 97 (78.2%) participants were AA, 19 (15.3%) Caucasian, and 8 (6.5%) of other races. The IPC survey results indicate that patient perceptions were associated with the extent of their SLE disease activity (see table below; p-values &lt;0.05 are starred). <h3>Conclusions</h3> Higher IPC scores indicating hurried communication were associated with higher disease activity, while higher IPC scores indicating effective and compassionate patient-centered interactions were associated with lower disease activity. Our findings highlight the potential impact of physician-patient interaction on SLE outcomes as perceived by the patient. <h3>Acknowledgement</h3> This research (GHO-11–3366) was funded by GSK. <h3>Disclosure of Interest</h3> C. Drenkard Grant/research support from: GSK, G. Bao: None declared, H. Kan Shareholder of: GSK, B. Pobiner Shareholder of: GSK, Employee of: GSK, P. Julie Shareholder of: GSK, Employee of: GSK, W. Eastman Shareholder of: GSK, Employee of: GSK, S. S. Lim Grant/research support from: GSK
Wilfrid T Fothergill
Authors: John Fothergill
Journal: BMJ (2016)

Wilfrid T Fothergill, affectionately known as “Pip,” arrived in Bennekom, a small town near Arnhem in the Netherlands, in 1978, when he became a partner in the anaesthetic practice covering the local hospital, the Streetziekenhuis. His practice grew and merged over several years, and he continued working until …
Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).
Authors: Victor A. Chow, Kathleen Shannon Dorcy, Stephen H. Petersdorf, Kelda M. Gardner, Pamela S. Becker, Roland B. Walter, John M. Pagel, Paul C. Hendrie, Andrei R. Shustov, Janis L. Abkowitz, Frederick R. Appelbaum, Elihu H. Estey
Journal: Blood (2010)
Methotrexate treatment and risk for cutaneous malignant melanoma: a retrospective comparative registry-based cohort study
Authors: S. Polesie, M. Gillstedt, H.H. Sönnergren, A. Osmancevic, J. Paoli
Journal: British Journal of Dermatology (2016)

Methotrexate (MTX) is frequently used as an immunosuppressive drug in inflammatory diseases. It is controversial and it has not been thoroughly investigated whether MTX increases the risk of cutaneous malignant melanoma (CMM).The aim of the present study was to investigate whether MTX exposure increases the risk for CMM.A retrospective cohort study was conducted using statistics from the National Board of Health and Welfare. All patients over 18 years in the time period August 2005 to December 2014 that were dispensed MTX from Swedish pharmacies were registered (n = 101 966). For every MTX-exposed patient, five age- and sex-matched patients who had been dispensed a random drug other than MTX during the same time period were randomly selected (n = 509 279). The lists were matched with the Swedish Cancer Registry.Overall, a small but statistically significant (P < 0·001) risk increase for CMM was observed in MTX-exposed patients compared with patients without MTX exposure. The Kaplan-Meier estimates for the 5-year risk of CMM was 0·48% [95% confidence interval (CI) 0·43-0·53] in the MTX-exposed group and 0·41% (95% CI 0·39-0·43) in the MTX-unexposed group. However, in a subgroup analysis, the difference between the groups was preserved only in women older than 70 years at treatment start. Moreover, there was no significant difference in incidences between the MTX-exposed and MTX-unexposed patients in the time period.Our results suggest a small but significant increase in risk for CMM in patients treated with MTX. However, the risk increase observed was considerably lower than in earlier observations.
Whole Genome Sequencing Defines the Clonal Architecture and Genomic Evolution in Myeloma: Tumor Heterogeneity with Continued Acquisition of New Mutational Change
Authors: Nikhil C. Munshi, Hervé Avet-Loiseau, Philip J. Stephens, Graham R Bignell, Yu-Tzu Tai, Masood Shammas, Cheng Li, Parantu K Shah, Mariateresa Fulciniti, Jagannath Pal, Ankit V Vahia, Paul G. Richardson, Stephane Minvielle, Peter Campbell, Kenneth C. Anderson, Andrew Futreal
Journal: Blood (2011)
Serum Hepcidin Levels Correlate with Phenotypes of the Metabolic Syndrome At Population Level
Authors: Nicola Martinelli, Michela Traglia, Natascia Campostrini, Ginevra Biino, Sara Previtali, Michela Corbella, Cinzia Sala, Fabiana Busti, Corrado Masciullo, Daniele Manna, Iwan Buetti, Giorgio Pistis, Oliviero Olivieri, Daniela Toniolo, Clara Camaschella, Domenico Girelli
Journal: Blood (2011)
AB0408 Factors That Influence Therapy in Patients with Undifferentiated Connective Tissue Disease
Authors: D.P. Pena, A.D. Askanase
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To compare clinical and immunological characteristics in patients with undifferentiated connective tissue disease (UCTD) treated with hydroxychloroquine (HCQ) in a large academic clinical practice. <h3>Methods</h3> This cross-sectional study included all patients diagnosed with UCTD according to the preliminary classification criteria (1), that seen at the Columbia University Lupus Clinic in New York, from January to December 2015. Clinical and immunological variables were ascertained by clinical evaluation and chart review. Chi squared tests were used to compare the following characteristic between treated and untreated patients: demographic characteristics, number of ACR criteria, SLICC criteria, individual symptoms and laboratory values. <h3>Results</h3> Eighty-three patients were identified; 93% were female, mean age at diagnosis of 44 years ±14.9; 67% were Caucasian, 20% Hispanic and 11% Black/African American; median disease duration of 3.91 years ±5.35. The most prevalent symptoms that required medical attention were arthralgia (81%), arthritis (46%), Raynaud (41%), fatigue (32%) and sicca symptoms (30%). All patients had positive antinuclear antibody (ANA) titers, 87% had titers above 1:640, with speckled pattern in 71% of patients. Interestingly, 16% of the patients studied met SLICC SLE criteria. Half of the patients, 42 (51%) were treated with HCQ and 41 (49.3%) were not treated. The patients treated with HCQ were more likely to meet SLICC criteria (10 vs. 3, respectively; p=0.03), have a history of arthralgia (38 vs. 29; p=0.02), arthritis (28 vs. 10; p=0.0001), and fatigue (25 vs. 14; p=0.02). A history of low complement was more prevalent in the treated group (12 vs. 3, p=0.01). <h3>Conclusions</h3> Data from this single-center cohort of patients with UCTD show that patients treated with HCQ by their rheumatologist are more likely to have multiple clinical criteria and low complement compared to those that were not treated. These data suggest that rheumatologist treat pre-clinical autoimmunity in the setting of clinical symptoms. None of patients were treated based on serologies alone. Longitudinal studies are needed to evaluate the long-term impact of HCQ on outcomes in patients with UCTD. <h3>References</h3> Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 1999;17:615–20. <h3>Disclosure of Interest</h3> None declared
Nanoparticle‐Based Targeting and Detection of Microcavities
Authors: Nathan A. Jones, Sywe‐Ren Chang, William J. Troske, Brian H. Clarkson, Joerg Lahann
Journal: Advanced Healthcare Materials (2016)

Although dental caries is the most prevalent oral disease worldwide, currently, many dentists continue to use the traditional mirror and probe (dental explorer) method of caries diagnosis. This method of caries detection has the drawback that it is often difficult to distinguish between active and inactive carious lesions. In this work, novel bio-based nanoparticles are developed to specifically detect active caries in vitro. The nanoparticles are made from a cationic fluorescein-labeled food-grade starch in order to fluoresce when illuminated by a standard dental curing light, and to degrade in the oral cavity into nontoxic compounds after detecting the active carious lesion. When exposed to extracted human teeth, cationic fluorescent (+5.8 ± 1.2 mV) nanoparticles (size 101 ± 56 nm) selectively illuminate active caries, but not the healthy tooth surface. Two-photon microscopy confirms the selective binding and accumulation of cationic fluorescent nanoparticles into microscopic carious pores in enamel. These novel nanoparticles provide a unique method to assist in the early diagnosis of active carious lesions with the potential to directly impact dental treatment.
90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.
Authors: Jane N. Winter, David Inwards, Stewart Spies, Gregory Wiseman, David Patton, William Erwin, Alfred Rademaker, Stephanie Williams, Martin S. Tallman, Ivana Micallef, Jayesh Mehta, Seema Singhal, Andrew Evens, Michael Zimmer, Arturo Molina, Christine White, Leo I. Gordon
Journal: Blood (2006)
Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis
Authors: Damiano Rondelli, Judith D. Goldberg, Roberto Marchioli, Luis Isola, Tsiporah B. Shore, Josef T. Prchal, Andrea Bacigalupo, Alessandro Rambaldi, Rebecca B. Klisovic, Vikas Gupta, Bjorn Andreasson, Erin P. Demakos, Leah S. Price, Marco Scarano, Meir Wetzler, Alessandro M. Vannucchi, Vesna Najfeld, Giovanni Barosi, Lewis R. Silverman, Ronald Hoffman
Journal: Blood (2011)
Chromatin Remodeling Factor LSH is Upregulated by the LRP6-GSK3β-E2F1 Axis Linking Reversely with Survival in Gliomas
Authors: Desheng Xiao, Jun Huang, Yu Pan, Hao Li, Chunyan Fu, Chao Mao, Yan Cheng, Ying Shi, Ling Chen, Yiqun Jiang, Rui Yang, Yating Liu, Jianhua Zhou, Ya Cao, Shuang Liu, Yongguang Tao
Journal: Theranostics (2016)

The signaling pathway-based stratification in chromatin modification could predict clinical outcome more reliably than morphology-alone-based classification schemes in gliomas. Here we reported a role of the chromatin-remodeling factor lymphoid-specific helicase (LSH) in gliomas. Among astrocytomas of grade I to III and glioblastoma of grade IV, LSH were almost completely expressed in all cases, and strongly correlated with astrocytomas progression and poor prognosis of patients with astrocytomas and glioblastoma. Ectopic expression of LSH promoted tumor formation. Up-regulation of transcription factor E2F1 in astrocytomas and glioblastoma was associated with the progression of gliomas and correlated with LSH expression. Chromatin immunoprecipitation (ChIP) analysis showed transcription factor E2F1 were recruited to the promoter region of LSH, and depletion of E2F1 decreased LSH expression and cell growth. Moreover, glycogen synthase kinase-3β (GSK-3β), an intact complex of E2F1, were also highly expressed in astrocytomas and linked with astrocytomas progression and poor prognosis of patients with astrocytomas and glioblastoma. Inhibition of GSK3β increased the enrichment of E2F1 to the LSH promoter, in turn, increased LSH expression. Lipoprotein receptor-related protein 6 (LRP6), an upstream regulator of GSK3β signaling pathway, was highly expressed in gliomas. Knockdown of LRP6 decreased LSH expression through decrease of recruitment of E2F1 to the LSH promoter leading to inhibition of cell growth. Taken together, this study reveals evidence demonstrating a mechanism by which upregulated promoted gliomas. A mechanistic link between LSH expression and activation of the LPR6/ GSK3β/E2F1 axis in gliomas illustrates a novel role of LSH in malignant astrocytomas and glioblastoma.
FDG-PET Predicts Response to Fractionated Radioimmunotherapy with 90Y-Epratuzumab Anti-CD22 MAB in Patients with NHL.
Authors: Caroline Bodet-Milin, Caroline Rousseau, Loic Campion, Catherine Ansquer, Benoit Dupas, Noel Milpied, Beatrice Mahe, Jean-Francois Chatal, William A. Wegener, David M. Goldenberg, Francois Kraeber-Bodere
Journal: Blood (2005)
Continuous Drip Infusion of Low Dose Cytrabine and Etoposide with Granulocyte Colony-Stimulating Factor for Elderly Acute Myeloid Leukemia Patients Hardly Tolerable Intensive Chemotherapy - Phase II Study.
Authors: Nobuhiro Kanemura, Hisashi Tsurumi, Takeshi Hara, Senji Kasahara, Naoe Goto, Kenji Fukuno, Toshiki Yamada, Michio Sawada, Hisataka Moriwaki
Journal: Blood (2005)
CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p.
Authors: William G Wierda, Susan M O’Brien, Stefan H Faderl, Alessandra Ferrajoli, Charles Koller, Zeev Estrov, Jan A Burger, Susan Lerner, Hagop M. Kantarjian, Michael J Keating
Journal: Blood (2008)